Search

Mixed ionic‐electronic conducting (MIEC) membranes have gained growing interest recently for various promising environmental and energy applications, such as H₂ and O₂ production, CO₂ reduction, O₂ and H₂ separation, CO₂ separation, membrane reactors for production of chemicals, cathode development for solid oxide fuel cells, solar‐driven evaporation and energy‐saving regeneration as well as electrolyzer cells for power‐to‐X technologies. The purpose of this roadmap, written by international specialists in their fields, is to present a snapshot of the state‐of‐the‐art, and provide opinions on the future challenges and opportunities in this complex multidisciplinary research field. As the fundamentals of using MIEC membranes for various applications become increasingly challenging tasks, particularly in view of the growing interdisciplinary nature of this field, a better understanding of the underlying physical and chemical processes is also crucial to enable the career advancement of the next generation of researchers. As an integrated and combined article, it is hoped that this roadmap, covering all these aspects, will be informative to support further progress in academics as well as in the industry‐oriented research toward commercialization of MIEC membranes for different applications.

Tian Yan,1 Ze-Fan Wang,1 Xiao-Yu Wu,1 Quan Du,2 Wen-Hua Yu,2 Wei Hu,3 Yong-Ke Zheng,3 Ke-Yi Wang,4 Xiao-Qiao Dong2 1The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, People’s Republic of China; 2Department of Neurosurgery, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China; 3Department of Intensive Care Unit, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China; 4Clinical Laboratory Center, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of ChinaCorrespondence: Xiao-Qiao Dong, Department of Neurosurgery, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China, Email dxqhyy@163.comObjective: SIRT3 may act as a brain-protective factor. We measured the plasma SIRT3 levels of patients with intracerebral hemorrhage (ICH) and further determined the relationship between plasma SIRT3 and clinical outcome plus severity of ICH.Methods: In this prospective cohort study, we quantified plasma SIRT3 levels in 105 ICH patients and 72 healthy controls. Glasgow Coma Scale (GCS) score and hematoma volume were used to assess severity. Poor prognosis was defined as a Glasgow Outcome Scale (GOS) score of 1– 3 at 90 days after ICH.Results: Plasma SIRT3 levels were markedly lower in patients than in controls (median, 10.19 versus 13.17 ng/mL; P< 0.001). Among all patients, plasma SIRT3 levels were independently correlated with hematoma volume (beta, − 0.098; 95% confidence interval, − 0.158--0.039; t, − 3.282; P=0.001) and GCS score (beta, 0.465; 95% confidence interval, 0.107– 0.823; t, 2.576; P=0.011). A total of 46 cases had a poor prognosis at post-stroke 90 days. The plasma levels of SIRT3 significantly decreased in patients with a poor prognosis, com